packageRavulizumab

ravulizumab

Extends from Pharmacolibrary.Interfaces.PartialSubstance (Identity and physicochemical constants of one drug (Drugs.Substances)).

Information

Ravulizumab, a monoclonal antibody complement inhibitor, is used for paroxysmal nocturnal hemoglobinuria and is also studied or used for conditions such as myasthenia gravis, neuromyelitis optica, and atypical hemolytic uremic syndrome. It is an approved medicine, authorised in the European Union for paroxysmal nocturnal hemoglobinuria, and carries a boxed warning.

Summary written by glm-5.3-flash from Wikidata Q55641547 and the WHO ATC classification and the EMA medicines list; not checked by a person.

name:ravulizumab
ATC codes:L04AA43, L04AJ02
DrugBank:DB11580
Wikidata:Q55641547
molar mass:148000 g/mol (Drugs.Common 25.09, not verified)

Parameters

TypeNameDefaultDescription
Stringname (from PartialSubstance)""INN / common name
String[:]atcCodes (from PartialSubstance)fill("", 0)all WHO ATC codes of the drug
StringdrugbankId (from PartialSubstance)""e.g. DB00758
StringpubchemCid (from PartialSubstance)""PubChem compound id
StringchebiId (from PartialSubstance)""ChEBI id (number)
StringwikidataId (from PartialSubstance)""e.g. Q410238
Stringformula (from PartialSubstance)""molecular formula
Modelica.Units.SI.MolarMassM (from PartialSubstance)0molar mass; 0 = unknown
ReallogP (from PartialSubstance)Modelica.Constants.infoctanol-water partition coefficient (log10); inf = unknown